Vaxcyte (NASDAQ:PCVX) Insider Sells $454,900.67 in Stock

Vaxcyte, Inc. (NASDAQ:PCVX) insider Harpreet Dhaliwal sold 9,743 shares of the firm’s stock in a transaction on Wednesday, December 31st. The stock was sold at an average price of $46.69, for a total value of $454,900.67. Following the sale, the insider directly owned 23,928 shares of the company’s stock, valued at approximately $1,117,198.32. This represents a 28.94% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Vaxcyte Stock Up 0.7%

Shares of NASDAQ PCVX opened at $46.46 on Monday. Vaxcyte, Inc. has a 12 month low of $27.66 and a 12 month high of $93.77. The business has a fifty day simple moving average of $45.88 and a 200-day simple moving average of $38.74. The company has a market cap of $6.08 billion, a price-to-earnings ratio of -9.60 and a beta of 1.34.

Vaxcyte (NASDAQ:PCVX) last posted its quarterly earnings data on Tuesday, November 4th. The company reported ($1.56) EPS for the quarter, missing analysts’ consensus estimates of ($1.27) by ($0.29). During the same period in the previous year, the business earned ($0.83) EPS. As a group, sell-side analysts expect that Vaxcyte, Inc. will post -4.21 EPS for the current fiscal year.

Wall Street Analyst Weigh In

PCVX has been the topic of several research analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vaxcyte in a research note on Tuesday, October 14th. Leerink Partners set a $77.00 price target on shares of Vaxcyte and gave the stock an “outperform” rating in a report on Wednesday, November 19th. The Goldman Sachs Group started coverage on shares of Vaxcyte in a research note on Friday, September 12th. They issued a “neutral” rating and a $38.00 price objective on the stock. Finally, BTIG Research reiterated a “buy” rating and issued a $85.00 target price on shares of Vaxcyte in a research report on Monday, November 10th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Vaxcyte currently has an average rating of “Moderate Buy” and a consensus target price of $97.83.

Hedge Funds Weigh In On Vaxcyte

A number of hedge funds have recently added to or reduced their stakes in the company. AlphaQuest LLC acquired a new stake in Vaxcyte in the first quarter valued at approximately $33,000. Allworth Financial LP raised its holdings in shares of Vaxcyte by 148.9% during the 3rd quarter. Allworth Financial LP now owns 1,222 shares of the company’s stock valued at $44,000 after purchasing an additional 731 shares in the last quarter. Aster Capital Management DIFC Ltd bought a new position in shares of Vaxcyte during the 3rd quarter valued at $45,000. CIBC Private Wealth Group LLC lifted its stake in shares of Vaxcyte by 22,500.0% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 1,356 shares of the company’s stock valued at $49,000 after purchasing an additional 1,350 shares during the last quarter. Finally, CWM LLC boosted its holdings in Vaxcyte by 197.3% in the second quarter. CWM LLC now owns 1,680 shares of the company’s stock worth $55,000 after purchasing an additional 1,115 shares in the last quarter. Institutional investors and hedge funds own 96.78% of the company’s stock.

About Vaxcyte

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.